RESEARCH MONOGRAPH · KDC-MN-208

Desvenlafaxine

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

75/100

Venlafaxine's metabolite repackaged as a drug. Modest improvement over the parent, mostly a CYP2D6 workaround

Desvenlafaxine is the O-desmethyl metabolite of venlafaxine, brought to market in 2008 by Wyeth as Pristiq with the perfectly reasonable pharmacological argument that bypassing the CYP2D6 metabolism step would produce more predictable plasma levels and less inter-individual variability. Whether that justified a new drug application versus just dosing venlafaxine more thoughtfully is one of those evergreen pharma-strategy debates that academic-detailing studies actually examined.

Pharmacology is straightforward: balanced SNRI with SERT inhibition somewhat stronger than NET (closer to 10:1) and minimal off-target receptor activity. Half-life is around 11 hours, primarily glucuronidated and renally cleared, which means the CYP2D6 polymorphism variability that affects venlafaxine basically disappears. That's a real pharmacokinetic advantage, just not necessarily a clinical one for most patients.

The clinical efficacy data is reasonable but unremarkable. MDD response and remission rates in placebo-controlled trials are roughly equivalent to venlafaxine, the comparative trials against duloxetine are mixed, and meta-analyses don't really separate desvenlafaxine from the rest of the SNRI class. The discontinuation profile is somewhat gentler than venlafaxine because of the longer effective half-life, but still recognizably SNRI-class with the standard brain-zap pattern.

What's interesting research-wise: desvenlafaxine bypasses essentially all of the CYP-mediated drug-drug interaction surface that venlafaxine has, which makes it a useful tool compound for studying SNRI pharmacology in subjects on multiple medications. For polypharmacy research populations or animal models where you want consistent plasma levels without metabolizer-phenotype confounds, desvenlafaxine has technical advantages over the parent.

What we don't like is the commercial positioning. Pristiq was launched with a substantial price premium over venlafaxine while offering modest clinical improvements for most patients, which is the kind of pharma move that fuels reasonable skepticism. The molecule has been generic in the US since 2017, which has improved the value calculation considerably.

Sourcing is straightforward, off-patent for years, reference standards from USP / EP. For research applications where consistent SNRI pharmacology without CYP2D6 confounds matters, it's a reasonable choice. For most clinical purposes it's basically venlafaxine with cleaner kinetics, and the marketing premium was always larger than the pharmacological differentiation deserved.

Evidence: 80
Mechanism: 85
Reliability: 80
Safety: 75
Sourcing: 88
Value: 75
Signal: 60
Staying power: 60

Plain-language summary Intrigue 50 / 100

Desvenlafaxine (Pristiq) is the major active leftover of venlafaxine, repackaged and sold on its own by Wyeth and Pfizer starting in 2008. The therapeutic logic was that giving the metabolite directly bypasses a liver enzyme called CYP2D6, which is genetically variable: some people break venlafaxine down quickly, others slowly, and that variability creates unpredictable blood levels. Skipping the conversion step gives flatter, more uniform pharmacology across patients. Mechanistically it does the same thing as the parent: blocks both the serotonin and norepinephrine pumps, with a slightly more balanced ratio between the two. Approved for major depressive disorder. Most prescribers consider it modestly different from generic venlafaxine, not dramatically so. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Active metabolite of venlafaxine (SNRI)

The major active metabolite of venlafaxine; a pure SNRI marketed separately to bypass CYP2D6 polymorphism.

Abstract

Desvenlafaxine (4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol; CAS 93413-62-8; molecular formula C16H25NO2; molecular weight 263.38) is the O-desmethylated active metabolite of venlafaxine, marketed as Pristiq by Wyeth/Pfizer after FDA approval in 2008. The compound is a structurally similar SNRI to venlafaxine with comparable SERT (Ki approximately 40 nM) and NET (Ki approximately 558 nM) affinity but a more balanced ratio than the parent compound, producing meaningful NET inhibition at lower doses. The principal pharmacokinetic advantage is bypass of CYP2D6 metabolism: desvenlafaxine is conjugated and excreted directly without further hepatic transformation, producing flat steady-state concentrations across CYP2D6 phenotypes and minimal drug-drug interaction potential. Plasma half-life is approximately 11 hours. Discontinuation syndrome is comparable to venlafaxine. Used as a reference SNRI compound when CYP2D6 variability is undesirable.

Mechanism of action

Direct SNRI activity, more balanced SERT/NET ratio than venlafaxine. Bypasses CYP2D6, providing flat PK across phenotypes.

Reported research dose ranges

Reported research dose ranges in the literature.

References

Sopko MA Jr, et al. Desvenlafaxine: another me-too drug? Ann Pharmacother 2008.
Liebowitz MR, et al. Efficacy of desvenlafaxine in major depressive disorder. Neuropsychiatr Dis Treat 2013.
Preskorn S, et al. Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6. J Clin Psychopharmacol 2007.

Read the full monograph

Available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-208

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Desvenlafaxine

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs